Using ganciclovir to stop cytomegalovirus from reactivating in patients with severe respiratory failure and sepsis

Who could benefit from this research

What this research studies

This research investigates the potential of the antiviral drug ganciclovir to prevent the reactivation of cytomegalovirus (CMV) in adults suffering from acute respiratory failure due to sepsis. The study will involve a phase 3 randomized placebo-controlled trial, where participants will receive either ganciclovir or a placebo to assess its safety and effectiveness. The research aims to improve clinical outcomes for critically ill patients by addressing the complications associated with CMV reactivation. A dedicated Data Coordinating Center will manage the trial's data and statistical analysis to ensure robust results.

Why it matters

Where this research is happening

• Fred Hutchinson Cancer Center
  Seattle, United States Active

Researchers

• Principal investigator: Leisenring, Wendy M — Fred Hutchinson Cancer Center
• Study coordinator: Leisenring, Wendy M

Related research

Other NIH-funded projects on the same topics.

• Understanding which patients and hospital care pathways affect outcomes after ICU vs ward care for ARF and sepsis

  A big study using hospital records to figure out which patients with acute respiratory failure and sepsis do best when admitted to ICUs versus general wards.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11372276

• Understanding how care decisions affect outcomes for patients with breathing problems and sepsis

  This project looks at hospital records to understand how decisions about where patients with severe breathing issues and sepsis receive care affect their recovery.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11160556

• Understanding the risks of acute respiratory failure in patients with hospital-onset sepsis

  This study looks at how patients with hospital-onset sepsis might face different chances of developing breathing problems, and it aims to find better ways to treat those at higher risk so they can get the care they need to feel better.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11082526

• Understanding why critically ill patients with respiratory failure and sepsis face health disparities.

  This study is looking into why critically ill patients with breathing problems and infections, especially those from minority backgrounds, often have worse health outcomes, and it aims to find ways to improve their care based on their unique challenges.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11018640

• Understanding how ICU and ward care affects patients with severe respiratory issues and sepsis

  This study looks at how choosing to treat patients with serious breathing problems and infections in either intensive care units or regular hospital rooms affects their recovery, with the aim of finding ways to improve care for these patients.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-10918227

• Using Ganciclovir to Prevent Cytomegalovirus Reactivation in Patients with Severe Respiratory Issues

  This study is looking at whether the antiviral medication ganciclovir can help prevent the reactivation of cytomegalovirus (CMV) in adults with severe respiratory failure caused by sepsis, to see if it can improve their recovery and reduce the time they spend on a ventilator and in the ICU.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-10916408

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.